Generex Biotechnology Corporation
GNBTQ
OTC PK
| 04/30/2021 | 01/31/2021 | 10/31/2020 | 07/31/2020 | 04/30/2020 | |
|---|---|---|---|---|---|
| Revenue | 20.70K | -- | 88.40K | 583.60K | 498.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.70K | -- | 88.40K | 583.60K | 498.70K |
| Cost of Revenue | 66.00K | 105.00K | 23.30K | 164.30K | 116.30K |
| Gross Profit | -45.30K | -105.00K | 65.10K | 419.30K | 382.40K |
| SG&A Expenses | 5.12M | 6.91M | 13.01M | 4.84M | 3.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.38M | 8.58M | 14.20M | 5.84M | 4.07M |
| Operating Income | -6.36M | -8.58M | -14.11M | -5.26M | -3.57M |
| Income Before Tax | 8.49M | -24.41M | -10.99M | -11.88M | -5.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.49M | -24.41M | -10.99M | -11.88M | -5.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 737.20K | 326.00K | 258.40K | 205.60K | 134.40K |
| Net Income | 9.22M | -24.08M | -10.73M | -11.67M | -5.63M |
| EBIT | -6.36M | -8.58M | -14.11M | -5.26M | -3.57M |
| EBITDA | -6.10M | -8.32M | -13.85M | -5.03M | -3.37M |
| EPS Basic | 0.08 | -0.22 | -0.11 | -0.15 | -0.07 |
| Normalized Basic EPS | 0.05 | -0.14 | -0.07 | -0.06 | -0.04 |
| EPS Diluted | -0.04 | -0.22 | -0.11 | -0.15 | -0.07 |
| Normalized Diluted EPS | 0.04 | -0.14 | -0.07 | -0.06 | -0.04 |
| Average Basic Shares Outstanding | 114.61M | 110.12M | 96.86M | 80.35M | 76.98M |
| Average Diluted Shares Outstanding | 140.41M | 110.12M | 96.86M | 80.35M | 76.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
